Abstract: Herein is reported a method for the co-cultivation of single deposited B-cells, which can be of any source, with EL-4 B5 feeder cells in a suitable co-cultivation medium. In the herein reported methods the EL-4 B5 cells have been irradiated with a dose of less than 40 Gy, preferably 9.5 Gy or less. Thereby the EL-4 B5 cells have a higher viability and maintain the ability to divide in cultivation at doses less than 6 Gy.

Abstract: A device for providing a droplet of a liquid stored in an interior of a vial is disclosed that includes a support body and a resilient dome portion mounted to the support body to form a chamber having air, with the dome portion being configured to create an air flow when activated by compression. The support body includes a vial seat, a nozzle, and air flow and transfer conduits. The support body is arranged, when the vial is received by the vial seat, such that the air flow conduit establishes an air connection between the vial interior and the chamber, the transfer conduit establishes a fluid connection between the vial and the nozzle, and, upon activation of the dome portion, the air flow delivers air into the vial that causes liquid to be transferred from the vial to the nozzle through the transfer conduit.

Abstract: A method of manufacturing a flexible container housing a drug substance is disclosed that includes forming a first compartment from a flexible sheet-like material, filling a liquid into the first compartment, sealing the first compartment, forming a second compartment from the flexible sheet-like material, filling a dry drug formulation into the second compartment, and sealing the second compartment. The method further involves lyophilizing the drug formulation inside a tubular cartridge, filling the second compartment by introducing the tubular cartridge through an opening of the second compartment such that an open end of the tubular cartridge is positioned distant from the opening of the second compartment, providing the drug formulation from the open end of the tubular cartridge into the second compartment, and withdrawing the tubular cartridge from the second compartment. The first and second compartments are separated by a frangible seal which opens when the first compartment is compressed.

Abstract: A device for transferring a liquid from a first vial to a second vial is disclosed having a dome portion configured to create an air flow when activated by compression and re-expansion, and a support body tightly supporting the dome portion to form a chamber with air therein. The support body includes first and second vial seats, and a transfer conduit. The first and second vial seats are arranged to receive the first and second vials. When the first and second vials are received in the first and second vial seats, the transfer conduit is arranged to establish a fluid connection between the first vial and the second vial. Upon activation of the dome portion, air is delivered into the first vial, thereby creating a pressure rise in the first vial which causes the liquid to transfer from the first vial to the second vial through the transfer conduit.

Abstract: The present invention relates to compounds of formula (I), wherein R1 to R4 are as described herein, and their pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds and methods of using the compounds.

Abstract: The present invention relates to combination therapies employing anti-CD20/anti-CD3 bispecific antibodies and 4-1BB (CD137) agonists, in particular 4-1 BBL trimer containing antigen binding molecules, the use of these combination therapies for the treatment of cancer and methods of using the combination therapies.

Abstract: A device for use in the detection of binding affinities comprises a substrate, a planar waveguide arranged thereon and having an outer surface. The device further comprises a grating for coupling coherent light of a predetermined wavelength into the planar waveguide such that the coherent light coupled into the planar waveguide propagates through the planar waveguide in a predetermined propagation direction. An evanescent field of the coherent light propagates along the outer surface of the planar waveguide. The outer surface of the planar waveguide has receptor molecules arranged thereon capable of binding target samples to the receptor molecules such that light of the evanescent field is diffracted by the target samples bound to the receptor molecules. The receptor molecules are arranged along a plurality of straight parallel lines such that a portion of the light of the evanescent field is diffracted by the target samples bound to the receptor molecules.

Abstract: The present invention relates to methods for separating multispecific CrossMab antibodies from light chain mispaired variants thereof in a solution comprising CrossMab bispecific antibodies and mispaired antibody variants thereof by hydrophobic interaction chromatography.

Abstract: The present invention relates to anti-VEGF/anti-IL-1beta antibodies and methods of using the same.

Abstract: The present invention relates to combination therapies employing PD-1 axis binding antagonists and LRRK2 inhibitors and, and the use of these combination therapies for the treatment of cancer.

Abstract: Herein is reported a method for producing an antibody comprising the steps of forming an antibody-antibody light chain affinity ligand complex, wherein the antibody light chain affinity ligand is immobilized on a solid phase, by applying a solution comprising the antibody to the immobilized antibody light chain affinity ligand, and incubating the complex formed in the previous step with one or more enzymes to modify the glycosylation of the antibody, thereby producing the antibody.

Abstract: Herein is reported a method for the determination of the binding affinity of a binder and its ligand comprising the step of determining based on the result of an immunoassay the fraction of free binder in a sample comprising binder, ligand and binder-ligand-complexes for at least two different binder:ligand ratios in the sample, and if the determined fraction of free binder is not comparable for all used binder:ligand ratios then the binder:ligand ratio in the sample is lowered and the sample is re-analyzed by the same immunoassay, and calculating based on the fraction of free binder in the previous step the binding affinity for the binder to its ligand.

Abstract: The present invention provides pharmaceutical compositions comprising a compound of formula (I) wherein A, R1, R2 and R3 are as described herein, as well as pharmaceutically acceptable salts thereof. Further the present invention is concerned with the manufacture of the pharmaceutical compositions comprising a compound of formula (I) and their use as medicaments.

Abstract: The invention relates to a novel process for the production of a linear P-linked oligonucleotide which comprises the removal of the acid labile 5?hydroxy protecting group at the 5?-O oligonucleotide with a detritylation solution comprising acetonitrile. The process allows to produce oligonucleotides with low content of depurination and N?1 impurities.

Abstract: The present invention generally relates to pH-dependent mutant interleukin-2 polypeptides that exhibit reduced IL-2 receptor binding at neutral pH and retained IL-2 receptor binding at reduced pH. In addition, the invention relates to immunoconjugates comprising said pH-dependent mutant IL-2 polypeptides, polynucleotide molecules encoding the pH-dependent mutant IL-2 polypeptides or immunoconjugates, and vectors and host cells comprising such polynucleotide molecules. The invention further relates to methods for producing the pH-dependent mutant IL-2 polypeptides or immunoconjugates, pharmaceutical compositions comprising the same, and uses thereof.

Abstract: The present invention relates to the combination therapy of specific PD-1-targeted IL-2 variant immunoconjugates with specific antibodies which bind human FAP and 4-1BB and optionally with an anti-CEA/anti-CD3 bispecific antibody.

Abstract: Disclosed herein are novel biomarkers for identifying patients, with cancer, likely to benefit from treatment with an anti-CD25 agent. Also disclosed are methods using said biomarkers for making a treatment decision—or monitoring treatment with an anti-CD25 agent as well as methods of treating a patient, with cancer, comprising administering an anti-CD25 agent based on prior use of the present biomarkers.

Abstract: The present invention relates to antibodies which bind to antigens on target cells and which target effector moieties to said cells, and to methods of using the same.

Abstract: The present invention relates to bispecific anti-CCL2 antibodies binding to two different epitopes on human CCL2, pharmaceutical compositions thereof, their manufacture, and use as medicaments for the treatment of cancers, inflammatory, autoimmune and ophthalmologic diseases.

Abstract: The present invention provides compounds of formula (I) wherein A, R1, R2 and R3 are as described herein, as well as pharmaceutically acceptable salts thereof. Further the present invention is concerned with the manufacture of the compounds of formula (I), pharmaceutical compositions comprising them and their use as medicaments.